MedTrace Logo

BEOVU in the Treatment of Dystrophy-related Macular Neovascular Degeneration

NCT04690062 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-12-30

No results posted yet for this study

Summary

Dystrophy-Related macular neovascularization degeneration occur is a vision threatening condition.The investigators evaluate the efficacy of BEOVU intravitreal treatment.

Conditions

  • Dystrophy, Retinal

Interventions

DRUG

Brolucizumab-Dbll

intravitreal injection of Brolucizumab (BEOVU)

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • Tarek Elhamaky, MD · Benha university faculty of medicine , INMC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-25
Primary Completion
2022-12-25
Completion
2022-12-30

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04690062 on ClinicalTrials.gov